Table 3.
Mean (SD) cannabinoid PK parameters in fasted beagle cross dogs (n = 6/dosing group; mixed gender) receiving a single oral dose of 1:20 THC:CBD CHE formulation at different dose sizes.
| Cannabinoid | Dose (mg/kg) | Tmax (h) | Cmax (ng/mL) | Dose-Adjusted Cmax (ng/mL per mg/kg)1 | T1/2β (h)2 | AUC0–12h (ng * h/mL) | Dose-Adjusted AUC0–12h (ng * h/mL per mg/kg)1 | T1/2λ (h)3 | AUClast (ng * h/mL) | “Steady-state” conc. (ng/mL)4 |
|---|---|---|---|---|---|---|---|---|---|---|
| CBD | 2 | 2.1 (1.0) |
213 (49) | 107A (24) |
2.5 (0.5) | 692 (292) |
346A (146) | 13.3 (4.1) |
759 (335) | NA |
| 5 | 1.9 (0.6) |
838 (304) | 168A (61) |
2.6 (0.4) | 2,433 (911) |
487A (182) | 23.1 (8.2) |
2,935 (1,244) | 1,264 (579) |
|
| 10 | 2.3 (0.5) |
1,868 (698) | 187A (70) |
2.3 (0.2) | 5,883 (2,181) |
588A (218) | 24.4 (9.5) |
7,239 (2,393) | NA | |
| THC | 0.1 | 2.1 (1.0) |
17.5 (5.5) | 175A (55.4) |
1.6 (1.5) | 43.5 (16.0) |
434.7A (160) | NA | NA | NA |
| 0.25 | 2.1 (0.5) |
67.6 (20.3) | 270.2A (81.3) |
1.9 (0.5) | 203.9 (73.3) |
815.5AB (293.1) | NA | NA | 79.4 (35.4) |
|
| 0.5 | 2.3 (0.5) |
138.3 (56.4) | 276.6A (112.8) |
1.9 (0.2) | 451.5 (178.8) |
903.0B (357.7) | NA | NA | NA | |
| CBC | 0.4 | 2.5 (1.7) |
17.7 (5.4) | 44.3 (13.4) |
2.1 (2.2) | 53.0 (26.1) |
132.4 (65.3) | NA | NA | NA |
| 1.0 | 1.8 (0.8) |
100.9 (30.3) | 100.9 (30.3) |
1.6 (0.4) | 220.3 (52.2) |
220.3 (52.2) | NA | NA | 69.0 (34.5) |
|
| 2.0 | 2.3 (0.6) |
191.6 (87.0) | 95.8 (43.5) |
1.9 (0.2) | 449.4 (160.8) |
224.7 (80.4) | NA | NA | NA | |
| 6-OH-CBD | 2 (CBD) | 3.4 (2.1) |
16.9 (8.2) | 8.5 (4.1) |
3.2 (0.7) | 94.5 (38.4) |
47.3 (19.2) | NA | NA | NA |
| 5 (CBD) | 2.2 (0.7) |
47.7 (18.1) | 9.5 (3.6) |
4.7 (0.9) | 247.8 (99.4) |
49.6 (19.9) | NA | NA | 41.7 (13.2) | |
| 10 (CBD) | 2.3 (0.6) |
94.9 (17.0) | 9.5 (1.7) |
5.1 (0.7) | 516.7 (62.6) |
51.7 (6.3) | NA | NA | NA |
Tmax, time to maximum concentration; Cmax, maximum concentration; AUC, area under the plasma concentration vs. time curve; T1/2, half−life; NA, notapplicable.
CBD and THC statistical analysis: Differing alphabetical superscripts in each column indicate statistically significant (p < 0.05) differences between mean values (ANOVA with post-hoc Tukey LSD).
Dose-adjusted value (parameter value divided by mg/kg dose).
T1/2β phase, from 4 to 12 h post-dose.
T1/2λ (terminal elimination) phase, from 12 to 48 h post-dose.
Taken 2 h after five consecutive CHE doses at 12 h intervals (n = 12), true steady-state concentrations. Unlikely reached at this time.